Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: real-world database analysis.
Ken-Ei SadaTakeo SuzukiSandra JoksaiteShinyoung JuJohn LogieGeorge MuJeremiah HweeHideaki KunishigeTakeo IshiiAmit AdlakHarini VadlamudiRafael Alfonso-CristanchoPublished in: Modern rheumatology (2023)
EGPA prevalence increased between 2005 and 2020. With the introduction of mepolizumab for EGPA in 2018, real-world OCS use, relapses and HCRU decreased.